Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Natasha on +44 1494 818 053 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Natasha Wilson
Executive Recruiter
+44 1494 818 053

Sometimes you don’t realise you need a new job until someone takes the time to help you find one. Zenopa was able to assess my situation and investigate multiple opportunities that suited my career ...
James, 2013

Baxter highlights success of Advate trials

4 August 2011 00:00 in Medical Company Product News

Baxter has revealed that additional trials of its Advate treatment have produced positive results, with the therapy demonstrating its safety, efficacy and inhibition capability.

Deborah Brady, business unit director for BioScience at the company, pointed out that this has previously been shown in clinical trial data, but it has now been backed up by the everyday experiences of international physicians.

Advate - or Antihaemophilic Factor (Recombinant), Plasma/Albumin-Free Method - was used on a broad range of patients, including those with severe to moderately severe haemophilia A and those who had been treated before.

"This publication provides further confidence to clinicians and patients that Advate
offers an effective, well-tolerated treatment," added Ms Brady.

Printed in the journal Haemophilia, the study focused on the experiences of pharmaceutical professionals in the US and 11 European Union nations.

Earlier this year, Baxter announced that it had raised more than £6,900 for Children in Need with the help of a Britain's Got Talent-style competition involving staff members. ADNFCR-8000103-ID-800690161-ADNFCR

Other news stories from 04/08/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd